The Jumpstart Our Business Startups (JOBS) Act has been a major catalyst for the recent surge in Biotech IPOs. There have been a total of 16 U.S.-listed biotech IPOs in the first half of the year, according to data from Renaissance Capital LLC. Since the JOBS Act has been signed into law all biotech companies who have gone public have used the new pathway. "The JOBS Act provided a safe harbor under which companies could talk to investors, educate them, and get feedback about whether the company was attractive to those investors," said Kenneth Moch, CEO of Chimerix Inc. (NASDAQ: CMRX).
Agios Pharmaceuticals Inc. (NASDAQ: AGIO) shares traded in the range of $25.38 to $26.35 Friday before settling to close at $25.87, an increase of 1.57 percent. The stock appears to be facing some resistance at the $26.79 and $27.97 levels with some support at $20.25. Shares of Agios Pharmaceuticals have fallen approximately 17.0 percent since it became public.
More information on Agios Pharmaceuticals and access to the free equity report can be found at:
Epizyme Inc. (NASDAQ: EPZM) shares traded in the range of $28.54 to $29.64 Friday before settling to close at $29.09, a decrease of 0.72 percent. The stock appears to be facing some resistance at the $31.57 and $37.45 levels with some support at $26.47. Shares of Epizyme have gained approximately 26.0 percent since it became public.
More information on Epizyme and access to the free equity report can be found at:
Onconova Therapeutics Inc. (NASDAQ: ONTX) shares traded in the range of $26.08 to $27.61 Friday before settling to close at $26.98, an increase of 4.74 percent. The stock appears to be facing some resistance at $29.88 with some support at the $26.02 and $18.47 levels. Shares of Onconova Therapeutics have gained approximately 35.0 percent since it became public.
More information on Onconova Therapeutics and access to the free equity report can be found at:
Intrexon Corp. (NYSE: XON) shares traded in the range of $22.80 to $23.65 Friday before settling to close at $23.42, an increase of 2.18 percent. The stock appears to be facing some resistance at the $24.32 and $29.99 levels with some support at $18.53. Shares of Intrexon have fallen approximately 5.0 percent since it became public.
More information on Intrexon and access to the free equity report can be found at:
Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.
Activate your always free membership by signing up at www.WallStreetFundamentals.com today.
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.
Wall Street Fundamentals
Leave a comment...